You need to upgrade your Flash Player to view this content.
What's New?
New patient education handout: Low Blood Glucose
Reviews the basics of low blood glucose in people with diabetes: what it is, why it may happen, and what to do if it happens.
|
Hypoglycemia guidelines from ADA/Endocrine Society
New guidelines for preventing and managing hypoglycemia in patients with diabetes. Download the slides in our Slide Library.
|
Clinical Insights® in Cardiovascular Disease
Latest issue: PCSK9 inhibitors for LDL-C lowering, statin therapy for LDL-C lowering in primary prevention, results from TRILOGY ACS, and more.
|
FDA allows marketing of first A1C test labeled for diagnosis of diabetes
FDA is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay for the diagnosis of diabetes by health care professionals. This is the first A1C test that FDA has allowed to be marketed for this use. The A1C tests currently on the market are FDA-cleared for monitoring blood glucose control, but not for diagnosing diabetes. Click here for more information.
|
Niacin/laropiprant products to be suspended worldwide
The European Medicines Agency (EMA) has recommended that the marketing, supply, and authorizations of three niacin/laropiprant products—Tredaptive, Pelzont, and Trevaclyn—for the treatment of adults with dyslipidemia be suspended across the European Union. The manufacturer, Merck, is working with regulatory agencies in all countries to suspend the availability of the product. Click here for more information.
|
FDA announces label changes for statins
FDA has announced safety label changes for statins. Changes include removal of routine monitoring of liver enzymes from drug labels; information about potential for cognitive side effects and reports of increased blood sugar and A1C has been added. The lovastatin label has also been extensively updated.
|
Not a member? What are you waiting for?
Sign up now for exclusive access to downloadable slides and other content from CCMDweb.org. Registration is free and takes just a moment to complete.
|
CCMDweb.org: Professional Education
for Cardiovascular Disease
CCMDweb.org is a premier destination for professional education, clinically relevant information, and programs that augment knowledge and practice gaps in cardiovascular disease (CVD) with the goal of enhancing patient care. Since 1996, CCMD has partnered with preeminent thought leaders to educate US healthcare professionals on issues spanning the cardiovascular disease (CVD) spectrum—highlighting many cardiometabolic conditions that individually or collectively contribute to cardiovascular risk, including dyslipidemia, atherosclerosis, diabetes, stroke, inflammation, and obesity.
A sample of the award-winning programs on CCMDweb.org:
- Slide library with nearly 1,000 downloadable slides exploring cardiometabolic diseases
- On-demand programs, including newsletters, case studies, and webcasts
- Clinical guidelines resources
- Expert commentaries on seminal research
- Patient education handouts
- And more!
Registration is free and unlocks premium content offerings and incentives. Sign up
here.
CCMDweb.org is the official website of The Committee on Cardiovascular and Metabolic Diseases™ (CCMD™), a multi-component independent educational initiative offering programs and resources focused on the management of cardiovascular and metabolic diseases as a means to prevent or reduce global cardiovascular risk. Click
here for more information about CCMD.
In the News
Statin Drugs May Increase Risk Of Diabetes
May 24, 2013 -- Certain statins - also known as cholesterol-lowering medications - could increase your risk of developing type 2 diabetes, a new study suggests. The risk was most significant in patients taking atorvastatin (Lipitor), rosuvastatin (Crestor) and simvastatin (Zocor), according to the study, published in BMJ...
|
Superiority Of Bivalirudin Over Heparin Questioned
May 24, 2013 -- Results from a large observational study reported at EuroPCR 2013 question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)...
|
|
|